Which has better earnings & valuation, TALK or BDSX?

Talkspace has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Talkspace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Talkspace $228.87M 3.82 $7.79M $0.01 522.00 Biodesix $88.50M 2.47 -$35.26M -$4.06 N/A

Is TALK or BDSX more profitable?

Talkspace has a net margin of 0.49% compared to Biodesix's net margin of -33.26%. Talkspace's return on equity of 1.03% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Talkspace 0.49% 1.03% 0.88% Biodesix -33.26% -2,101.40% -35.65%

Does the media prefer TALK or BDSX?

In the previous week, Talkspace had 2 more articles in the media than Biodesix. MarketBeat recorded 4 mentions for Talkspace and 2 mentions for Biodesix. Biodesix's average media sentiment score of 1.83 beat Talkspace's score of 1.02 indicating that Biodesix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Talkspace 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biodesix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer BDSX or CSTL?

In the previous week, Castle Biosciences had 2 more articles in the media than Biodesix. MarketBeat recorded 4 mentions for Castle Biosciences and 2 mentions for Biodesix. Biodesix's average media sentiment score of 1.83 beat Castle Biosciences' score of 1.10 indicating that Biodesix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodesix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Castle Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is FLGT or BDSX more profitable?

Fulgent Genetics has a net margin of -23.04% compared to Biodesix's net margin of -33.26%. Fulgent Genetics' return on equity of -3.24% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Fulgent Genetics -23.04% -3.24% -2.97% Biodesix -33.26% -2,101.40% -35.65%

Does the media favor FLGT or BDSX?

In the previous week, Fulgent Genetics had 3 more articles in the media than Biodesix. MarketBeat recorded 5 mentions for Fulgent Genetics and 2 mentions for Biodesix. Biodesix's average media sentiment score of 1.83 beat Fulgent Genetics' score of 0.92 indicating that Biodesix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biodesix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor BDSX or TOI?

In the previous week, Oncology Institute had 11 more articles in the media than Biodesix. MarketBeat recorded 13 mentions for Oncology Institute and 2 mentions for Biodesix. Biodesix's average media sentiment score of 1.83 beat Oncology Institute's score of 0.95 indicating that Biodesix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodesix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Oncology Institute 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BDSX or MCTA?

Biodesix currently has a consensus price target of $28.33, indicating a potential upside of 34.09%. Given Biodesix's stronger consensus rating and higher probable upside, equities analysts plainly believe Biodesix is more favorable than Charming Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodesix 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Charming Medical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, BDSX or MCTA?

Charming Medical has lower revenue, but higher earnings than Biodesix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodesix $88.50M 2.47 -$35.26M -$4.06 N/A Charming Medical N/A N/A N/A N/A N/A

Biodesix (BDSX) Competitors

$21.13 -0.29 (-1.35%)

Closing price 04:00 PM Eastern

Extended Trading

$21.69 +0.56 (+2.65%)

As of 07:59 PM Eastern

Compare

BDSX vs. TALK, CSTL, FLGT, TOI, and MCTA

Should you buy Biodesix stock or one of its competitors? MarketBeat compares Biodesix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biodesix include Talkspace (TALK), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Oncology Institute (TOI), and Charming Medical (MCTA). These companies are all part of the "healthcare" industry.

How does Biodesix compare to Talkspace?

Talkspace (NASDAQ:TALK) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

Talkspace presently has a consensus price target of $5.56, indicating a potential upside of 6.56%. Biodesix has a consensus price target of $28.33, indicating a potential upside of 34.09%. Given Biodesix's stronger consensus rating and higher probable upside, analysts plainly believe Biodesix is more favorable than Talkspace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talkspace	1 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Talkspace has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Talkspace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talkspace	$228.87M	3.82	$7.79M	$0.01	522.00
Biodesix	$88.50M	2.47	-$35.26M	-$4.06	N/A

57.4% of Talkspace shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 23.5% of Talkspace shares are held by insiders. Comparatively, 23.2% of Biodesix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Talkspace had 2 more articles in the media than Biodesix. MarketBeat recorded 4 mentions for Talkspace and 2 mentions for Biodesix. Biodesix's average media sentiment score of 1.83 beat Talkspace's score of 1.02 indicating that Biodesix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Talkspace	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biodesix	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Talkspace has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Biodesix has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

Talkspace has a net margin of 0.49% compared to Biodesix's net margin of -33.26%. Talkspace's return on equity of 1.03% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talkspace	0.49%	1.03%	0.88%
Biodesix	-33.26%	-2,101.40%	-35.65%

Summary

Talkspace beats Biodesix on 12 of the 17 factors compared between the two stocks.

How does Biodesix compare to Castle Biosciences?

Biodesix (NASDAQ:BDSX) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

Biodesix presently has a consensus target price of $28.33, suggesting a potential upside of 34.09%. Castle Biosciences has a consensus target price of $42.43, suggesting a potential upside of 83.51%. Given Castle Biosciences' higher probable upside, analysts clearly believe Castle Biosciences is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Castle Biosciences had 2 more articles in the media than Biodesix. MarketBeat recorded 4 mentions for Castle Biosciences and 2 mentions for Biodesix. Biodesix's average media sentiment score of 1.83 beat Castle Biosciences' score of 1.10 indicating that Biodesix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Castle Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Castle Biosciences has a net margin of -3.78% compared to Biodesix's net margin of -33.26%. Castle Biosciences' return on equity of -2.77% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-33.26%	-2,101.40%	-35.65%
Castle Biosciences	-3.78%	-2.77%	-2.30%

21.0% of Biodesix shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 23.2% of Biodesix shares are held by company insiders. Comparatively, 6.1% of Castle Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Castle Biosciences has higher revenue and earnings than Biodesix. Castle Biosciences is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	2.47	-$35.26M	-$4.06	N/A
Castle Biosciences	$344.23M	2.04	-$24.16M	-$0.44	N/A

Biodesix has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Castle Biosciences has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.

Summary

Castle Biosciences beats Biodesix on 11 of the 15 factors compared between the two stocks.

How does Biodesix compare to Fulgent Genetics?

Fulgent Genetics (NASDAQ:FLGT) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

Fulgent Genetics has a net margin of -23.04% compared to Biodesix's net margin of -33.26%. Fulgent Genetics' return on equity of -3.24% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-23.04%	-3.24%	-2.97%
Biodesix	-33.26%	-2,101.40%	-35.65%

Biodesix has lower revenue, but higher earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.80	-$60.51M	-$2.39	N/A
Biodesix	$88.50M	2.47	-$35.26M	-$4.06	N/A

Fulgent Genetics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Biodesix has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

Fulgent Genetics presently has a consensus target price of $27.00, suggesting a potential upside of 31.96%. Biodesix has a consensus target price of $28.33, suggesting a potential upside of 34.09%. Given Biodesix's stronger consensus rating and higher possible upside, analysts clearly believe Biodesix is more favorable than Fulgent Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

48.1% of Fulgent Genetics shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 36.2% of Fulgent Genetics shares are held by company insiders. Comparatively, 23.2% of Biodesix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Fulgent Genetics had 3 more articles in the media than Biodesix. MarketBeat recorded 5 mentions for Fulgent Genetics and 2 mentions for Biodesix. Biodesix's average media sentiment score of 1.83 beat Fulgent Genetics' score of 0.92 indicating that Biodesix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biodesix	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Fulgent Genetics beats Biodesix on 9 of the 17 factors compared between the two stocks.

How does Biodesix compare to Oncology Institute?

Biodesix (NASDAQ:BDSX) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Oncology Institute has a net margin of -7.42% compared to Biodesix's net margin of -33.26%. Oncology Institute's return on equity of 0.00% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-33.26%	-2,101.40%	-35.65%
Oncology Institute	-7.42%	N/A	-24.68%

Biodesix has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

Biodesix has higher earnings, but lower revenue than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	2.47	-$35.26M	-$4.06	N/A
Oncology Institute	$502.73M	1.23	-$60.61M	-$0.37	N/A

In the previous week, Oncology Institute had 11 more articles in the media than Biodesix. MarketBeat recorded 13 mentions for Oncology Institute and 2 mentions for Biodesix. Biodesix's average media sentiment score of 1.83 beat Oncology Institute's score of 0.95 indicating that Biodesix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Oncology Institute	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

21.0% of Biodesix shares are held by institutional investors. Comparatively, 36.9% of Oncology Institute shares are held by institutional investors. 23.2% of Biodesix shares are held by insiders. Comparatively, 4.4% of Oncology Institute shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Biodesix presently has a consensus target price of $28.33, suggesting a potential upside of 34.09%. Oncology Institute has a consensus target price of $8.40, suggesting a potential upside of 33.76%. Given Biodesix's stronger consensus rating and higher probable upside, analysts plainly believe Biodesix is more favorable than Oncology Institute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Biodesix beats Oncology Institute on 9 of the 17 factors compared between the two stocks.

How does Biodesix compare to Charming Medical?

Biodesix (NASDAQ:BDSX) and Charming Medical (NASDAQ:MCTA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

In the previous week, Biodesix had 1 more articles in the media than Charming Medical. MarketBeat recorded 2 mentions for Biodesix and 1 mentions for Charming Medical. Charming Medical's average media sentiment score of 1.93 beat Biodesix's score of 1.83 indicating that Charming Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Biodesix	Very Positive
Charming Medical	Very Positive

21.0% of Biodesix shares are held by institutional investors. 23.2% of Biodesix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Charming Medical has lower revenue, but higher earnings than Biodesix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	2.47	-$35.26M	-$4.06	N/A
Charming Medical	N/A	N/A	N/A	N/A	N/A

Biodesix currently has a consensus price target of $28.33, indicating a potential upside of 34.09%. Given Biodesix's stronger consensus rating and higher probable upside, equities analysts plainly believe Biodesix is more favorable than Charming Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Charming Medical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Charming Medical has a net margin of 0.00% compared to Biodesix's net margin of -33.26%. Charming Medical's return on equity of 0.00% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-33.26%	-2,101.40%	-35.65%
Charming Medical	N/A	N/A	N/A

Summary

Biodesix beats Charming Medical on 8 of the 12 factors compared between the two stocks.

Get Biodesix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDSX vs. The Competition

Export

Metric	Biodesix	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$221.82M	$9.53B	$6.85B	$12.45B
Dividend Yield	N/A	1.63%	2.68%	8.43%
P/E Ratio	-5.20	25.39	27.04	24.38
Price / Sales	2.47	17.88	524.25	93.51
Price / Cash	N/A	112.66	48.59	59.36
Price / Book	-68.16	6.04	10.80	6.33
Net Income	-$35.26M	$177.20M	$3.59B	$331.02M
7 Day Performance	3.88%	-1.70%	-2.24%	-1.09%
1 Month Performance	40.31%	7.27%	3.12%	-0.49%
1 Year Performance	237.86%	11.43%	26.30%	19.90%

Biodesix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDSX Biodesix	3.4867 of 5 stars	$21.13 -1.4%	$28.33 +34.1%	+247.1%	$221.82M	$88.50M	N/A	220	Positive News
TALK Talkspace	2.499 of 5 stars	$5.22 -0.5%	$5.56 +6.7%	+98.1%	$873.57M	$228.87M	522.02	500	News Coverage
CSTL Castle Biosciences	3.6187 of 5 stars	$23.64 -2.4%	$42.43 +79.5%	+16.9%	$716.82M	$344.23M	N/A	540	Positive News
FLGT Fulgent Genetics	3.2378 of 5 stars	$20.95 -2.1%	$27.00 +28.9%	+6.0%	$595.26M	$322.67M	N/A	1,315	News Coverage
TOI Oncology Institute	3.8429 of 5 stars	$5.50 +1.0%	$8.20 +49.2%	+99.7%	$543.02M	$545.76M	N/A	660	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDSX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biodesix (BDSX) Competitors

BDSX vs. TALK, CSTL, FLGT, TOI, and MCTA

How does Biodesix compare to Talkspace?

Summary

How does Biodesix compare to Castle Biosciences?

Summary

How does Biodesix compare to Fulgent Genetics?

Summary

How does Biodesix compare to Oncology Institute?

Summary

How does Biodesix compare to Charming Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDSX vs. The Competition

Biodesix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biodesix (BDSX) Competitors

BDSX vs. TALK, CSTL, FLGT, TOI, and MCTA

How does Biodesix compare to Talkspace?

Do analysts rate TALK or BDSX?

Which has better earnings & valuation, TALK or BDSX?

Do insiders and institutionals believe in TALK or BDSX?

Does the media prefer TALK or BDSX?

Which has more volatility & risk, TALK or BDSX?

Is TALK or BDSX more profitable?

Summary

How does Biodesix compare to Castle Biosciences?

Do analysts recommend BDSX or CSTL?

Does the media prefer BDSX or CSTL?

Is BDSX or CSTL more profitable?

Do institutionals and insiders have more ownership in BDSX or CSTL?

Which has better earnings and valuation, BDSX or CSTL?

Which has more risk & volatility, BDSX or CSTL?

Summary

How does Biodesix compare to Fulgent Genetics?

Is FLGT or BDSX more profitable?

Which has higher earnings & valuation, FLGT or BDSX?

Which has more volatility and risk, FLGT or BDSX?

Do analysts recommend FLGT or BDSX?

Do institutionals and insiders hold more shares of FLGT or BDSX?

Does the media favor FLGT or BDSX?

Summary

How does Biodesix compare to Oncology Institute?

Is BDSX or TOI more profitable?

Which has more risk and volatility, BDSX or TOI?

Which has higher earnings and valuation, BDSX or TOI?

Does the media favor BDSX or TOI?

Do insiders & institutionals have more ownership in BDSX or TOI?

Do analysts recommend BDSX or TOI?

Summary

How does Biodesix compare to Charming Medical?

Does the media prefer BDSX or MCTA?

Do insiders & institutionals believe in BDSX or MCTA?

Which has stronger valuation & earnings, BDSX or MCTA?

Do analysts rate BDSX or MCTA?

Is BDSX or MCTA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDSX vs. The Competition

Biodesix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools